Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera.bioRxiv. 2021 Jan 07B
Abstract
Rapidly spreading variants of SARS-CoV-2 that have arisen in the United Kingdom and South Africa share the spike N501Y substitution, which is of particular concern because it is located in the viral receptor binding site for cell entry and increases binding to the receptor (angiotensin converting enzyme 2). We generated isogenic N501 and Y501 SARS-CoV-2. Sera of 20 participants in a previously reported trial of the mRNA-based COVID-19 vaccine BNT162b2 had equivalent neutralizing titers to the N501 and Y501 viruses.
Links
Pub Type(s)
Preprint
Language
eng
PubMed ID
33442691
Citation
Xie, Xuping, et al. "Neutralization of N501Y Mutant SARS-CoV-2 By BNT162b2 Vaccine-elicited Sera." BioRxiv : the Preprint Server for Biology, 2021.
Xie X, Zou J, Fontes-Garfias CR, et al. Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera. bioRxiv. 2021.
Xie, X., Zou, J., Fontes-Garfias, C. R., Xia, H., Swanson, K. A., Cutler, M., Cooper, D., Menachery, V. D., Weaver, S., Dormitzer, P. R., & Shi, P. Y. (2021). Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera. BioRxiv : the Preprint Server for Biology. https://doi.org/10.1101/2021.01.07.425740
Xie X, et al. Neutralization of N501Y Mutant SARS-CoV-2 By BNT162b2 Vaccine-elicited Sera. bioRxiv. 2021 Jan 7; PubMed PMID: 33442691.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera.
AU - Xie,Xuping,
AU - Zou,Jing,
AU - Fontes-Garfias,Camila R,
AU - Xia,Hongjie,
AU - Swanson,Kena A,
AU - Cutler,Mark,
AU - Cooper,David,
AU - Menachery,Vineet D,
AU - Weaver,Scott,
AU - Dormitzer,Philip R,
AU - Shi,Pei-Yong,
Y1 - 2021/01/07/
PY - 2021/1/14/entrez
PY - 2021/1/15/pubmed
PY - 2021/1/15/medline
JF - bioRxiv : the preprint server for biology
JO - bioRxiv
N2 - Rapidly spreading variants of SARS-CoV-2 that have arisen in the United Kingdom and South Africa share the spike N501Y substitution, which is of particular concern because it is located in the viral receptor binding site for cell entry and increases binding to the receptor (angiotensin converting enzyme 2). We generated isogenic N501 and Y501 SARS-CoV-2. Sera of 20 participants in a previously reported trial of the mRNA-based COVID-19 vaccine BNT162b2 had equivalent neutralizing titers to the N501 and Y501 viruses.
UR - https://www.unboundmedicine.com/medline/citation/33442691/Neutralization_of_N501Y_mutant_SARS_CoV_2_by_BNT162b2_vaccine_elicited_sera_
DB - PRIME
DP - Unbound Medicine
ER -